Barinthus Biotherapeutics has announced a new partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford to advance a vaccine against Middle East respiratory syndrome (MERS).
The partnership aims to fast-track the development of Barinthus Bios’ vaccine candidate, VTP-500.
The collaboration will advance VTP-500 from early development to phase 2 clinical trials and into the development of an investigational ready reserve of 100,000 doses to be rapidly deployed in a clinical trial setting in preparation of a possible outbreak.
